Duke Customized Aortic Aneurysm Repair With Endovascular Stent-grafts - Duke CARES Trial

Chandler Long, MD30 enrolled

Overview

The purpose of this study is to see if physician modified endovascular grafts (PMEG) can be used safely for the treatment of aortic disorders. The surgeon will modify a commercially available graft tailored to the participant's anatomy for surgery. The researchers will follow participants for 5 years, which will require regular visits to the clinic for follow-up imaging and follow-up blood tests.

The primary objective of the clinical investigation Duke CARES Trial is to assess the use of physician-modification of commercially available, off-the-shelf, endovascular stent-grafts to treat juxtarenal, pararenal and paravisceral complex abdominal aneurysms or thoracoabdominal aneurysms in high-risk for open surgery subjects having appropriate anatomy. The primary intent of the study is to assess safety and efficacy of the device acutely (i.e., treatment success and technical success), at 30 days (i.e., the rate of major adverse events (MAE)) and at 6 months, 12 months and annually to 5 years (i.e., the proportion of treatment group subjects that achieve and maintain treatment success). Additionally, the study will assess domains for improvement of patient selection criteria, device design, operative techniques, and follow-up regimens to benefit patients undergoing complex endovascular aneurysm repair Main Study - Statistical Cohort Physician Modified Endovascular Grafts are indicated for endovascular repair of juxtarenal, pararenal, paravisceral and thoracoabdominal aneurysms, in high-risk for open surgery subjects having appropriate anatomy as defined in the eligibility section. Non-statistical cohort Patients with life-threatening aortic disease who have no acceptable surgical or endovascular alternatives will be allowed to receive treatment under this IDE. Enrollment of these patients under the IDE permits systematic data collection and FDA oversight, while their separation from the primary study cohort preserves the integrity of the safety and effectiveness analyses. This approach provides a treatment option for critically ill patients by offering access to a potential therapeutic option within a regulated and monitored environment without compromising the scientific validity of the trial. The patients in this cohort will follow standard of care, which includes follow-up at 1 month, 6 months and then annually. Data collection and presentation in this cohort will be consistent with the primary study cohort; however, data from this cohort will not be included in the statistical analysis.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Aortic Disorders

Interventions

Physician Modified Endovascular GraftDEVICE

The participant's surgeon will modify a commercially available graft tailored to their anatomy for their surgery. All components used to create the final device (PMEG), made specifically for each participant and tailored to their individual anatomy, are FDA-approved, although the final graft itself (the PMEG) is considered investigational.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

MAIN COHORT INCLUSION CRITERIA: * A participant may be entered into the study if the participant has at least one of the following: An aneurysm with a maximum diameter of \> 5.5 cm or 2 times the normal diameter just proximal to the aneurysm using orthogonal (i.e, perpendicular to the centerline) measurements; Aneurysm with a history of growth \> 0.5 cm in 6 months; Saccular aneurysm deemed at significant risk for rupture; Symptomatic aneurysm; Ruptured aneurysm AND * Extent of aorta to be treated: juxtarenal, pararenal that include 1 or 2 renal and/or accessory renal arteries, paravisceral that includes celiac artery and/or superior mesenteric artery, and/or thoracoabdominal * High risk of morbidity and mortality with open surgical repair as defined by: a. Anatomic Criteria (Previous abdominal surgery; Previous thoracotomy; Previous aortic surgery) b. Physiologic Criteria (ASA Category III or higher; Age \>70 years; Previous myocardial infarction, coronary artery disease, or coronary artery stent; Coronary stress test with a reversible perfusion defect; Congestive heart failure (CHF); Chronic obstructive pulmonary disease (COPD)) * Iliac or femoral access vessel morphology that is compatible with vascular access techniques, devices or accessories, with or without use of a surgical conduit * Nonaneurysmal aortic segment proximal to the aneurysm (neck) with a minimum neck length of 25 mm (Diameter in the range of 18 mm - 42 mm; Angle less than 60o relative to the axis of the aneurysm; Angle less than 60o relative to the axis of the suprarenal aorta); * Minimum branch vessel diameter greater than 5 mm * Iliac artery distal fixation site greater than 20 mm in length and diameter in the range of 9 mm - 21 mm (for use of ZFEN) * Contralateral iliac artery distal fixation site greater than 20 mm in length and diameter in the range of 7.5 mm - 20 mm. * Age: ≥ 18 years old * Life expectancy: \> 2 years EXCLUSION CRITERIA: GENERAL EXCLUSION CRITERIA: * Able to be treated in accordance with the instructions for use with a currently marketed endovascular prosthesis * Unwilling to comply with the follow-up schedule * Inability or refusal to give informed consent by subject or legal representative * Pregnant or breastfeeding * Prefers to receive treatment at another hospital with access to a non-physician modified endovascular prosthesis * Refusal of blood transfusions for religious or personal reasons * Participation in another investigational clinical or device trial, with the exception of another investigational endovascular stent-graft protocol or percutaneous aortic valve protocol, not encompassed by the IDE protocol and performed remotely from the fenestrated procedure (\> 30 days). Examples include remote (\>30 days) participation in a thoracic, abdominal or iliac branch device trial, or participation in a percutaneous aortic valve trial. * Mycotic aneurysm or evidence of active systemic infection MEDICAL EXCLUSION CRITERIA: * Known sensitivities or allergies to the materials of construction of the devices, including nitinol (nickel, titanium), polyester, polypropylene, gold, stainless steel, and/or solder (tin, silver). * Known hypersensitivity or contraindication to anticoagulation or contrast media that cannot be adequately medically managed * Uncorrectable coagulopathy * Body habitus that would inhibit x-ray visualization of the aorta or exceeds the safe capacity of the equipment • Morbid obesity (BMI ≥ 40 or BMI 30-39.9 with comorbidities) * Major surgical or interventional procedure unrelated to the treatment of the aneurysm planned \< 30 days of the endovascular repair * Unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina) * Baseline creatinine greater than 2.0 mg/dL * History of connective tissue disorders (e.g., Marfan Syndrome, Ehler's Danlos Syndrome) * Deemed a high risk due to significant comorbidities, adjudicated by severity according to the Society for Vascular Surgery reporting standards for endovascular aortic repair involving the renal-mesenteric arteries ANATOMICAL EXCLUSION CRITERIA: * Thrombus or excessive calcification within the neck of the aneurysm * Presence of significant thrombus and/or excessive calcification within the intended proximal or distal seal zone of the aneurysm. * Branch stenosis \> 75% (if left untreated) * Anatomy that would not allow maintenance of at least one patent hypogastric artery * Inadequate femoral or iliac access to accommodate the required delivery systems. * Requirement for iliac conduit in cases of inadequate femoral/iliac access * Absence of a suitable non-aneurysmal segment of distal thoracic aorta and significant aortic tortuosity. * Target vessel anatomy not compatible with fenestrated or branched stent graft incorporation, including vessels with severe stenosis, tortuosity and/or insufficient size to accommodate stent graft placement. * Early target vessel bifurcation precluding safe or effective stent graft placement. * Unsuitable iliac artery fixation site and/or anatomy for iliac limb extension or iliac branch device placement, as defined by the device instructions for use Note: Patients with life-threatening aortic disease who have no acceptable surgical or endovascular alternatives will be allowed to receive treatment under this IDE in the non-statistical cohort Non-statistical Cohort This cohort will include patients who meet the inclusion criteria and meet any of the above exclusion criteria\* with the exception of the following: * Able to be treated in accordance with the instructions for use with a currently marketed endovascular prosthesis * Subject prefers to receive treatment at another hospital with access to a custom-made endovascular prosthesis * Refusal to give informed consent by the subject or legal representative. Note: Inability to consent prior to surgery will not be exclusionary if it is for life-saving measures. * Known sensitivities or allergies to the materials of construction of the devices will be allowed in a life-threatening situation where the patient would not survive open surgery.

Locations (1)

Duke University Health System

Durham, North Carolina, United States

RECRUITING

Outcomes

Primary Outcomes

Incidence of major adverse events (MAE)

The primary safety endpoint is freedom from major adverse events (MAE) at 30 days or during hospitalization if this exceeds 30 days. MAE include death, bowel ischemia, myocardial infarction, paraplegia, renal failure, respiratory failure, stroke, and estimated procedural blood loss \> 1000 cc.

Time frame: 30 days, or during hospitalization if this exceeds 30 days

Proportion of study participants with treatment success

Treatment success requires all the following criteria to be met: * Technical success * Absence of death from the initial procedure, secondary intervention, or aorta-related cause * Absence of persistent type I or type III endoleak * Absence of aneurysm sac expansion \>5 mm * Absence of device migration \>10 mm * Absence of failure due to device integrity issues * Absence of aneurysm rupture * Absence of conversion to open surgical repair * Device infection or thrombosis

Time frame: 1 year

Secondary Outcomes

Technical success

Technical success - defined as the successful introduction, deployment and withdrawal of the device, in the absence of surgical conversion or mortality, absence of Type I and III endoleak, absence of branch occlusion ensuring unimpeded flow to the branch vessel(s) intended for preservation or absence of graft limb obstruction.

Time frame: Within 24 hours

Incidence of death

Time frame: 30 days

Incidence of bowel ischemia

Time frame: 30 days

Incidence of myocardial infarction

Time frame: 30 days

Incidence of paraplegia

Central Contacts

Ellen R Burkett, MSHS

CONTACT

9196811878 ellen.burkett@duke.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.